Back to today’s briefing

Story perspectives

FDA Approves First Oral Treatment for Postpartum Depression

9/2/2025

26 4 Full Breakdown

Summary

Story summary

The FDA approved ZURZUVAE™ (zuranolone) as the first oral treatment for postpartum depression (PPD), providing rapid relief.
Traditional treatments can take weeks to be effective, limiting timely care for many women.
PPD affects approximately one in seven women worldwide, influencing both maternal and infant health.
Experts stress the importance of immediate treatment options to assist mothers during this crucial time.

1 of 1

Story summary

The FDA approved ZURZUVAE™ (zuranolone) as the first oral treatment for postpartum depression (PPD), providing rapid relief.
Traditional treatments can take weeks to be effective, limiting timely care for many women.
PPD affects approximately one in seven women worldwide, influencing both maternal and infant health.
Experts stress the importance of immediate treatment options to assist mothers during this crucial time.